Cardiopulmonary bypass reduces myocardial oxidative stress, inflammation and increases c-kit(+)CD45(-) cell population in newborns.

体外循环可降低新生儿心肌氧化应激、炎症,并增加 c-kit(+)CD45(-) 细胞数量

阅读:5
作者:Petersen Johannes, Kazakov Andrey, Böhm Michael, Schäfers Hans-Joachim, Laufs Ulrich, Abdul-Khaliq Hashim
BACKGROUND: The aim of this study was to characterize the influence of cardiopulmonary bypass (CPB) on myocardial remodeling in newborns and children. METHODS: Biopsies from the right atrium were taken before and after CPB from 4 newborns (5-11 days old) and 7 children (8 months-16 years old). Immunostainings on 10 µm heart tissue frozen sections were performed to detect c-kit(+) cells, leukocytes (CD45(+) cells), Ki67(+) cycling cells. The percentage of 8-hydroxy-guanosine (8-dOHG)(+)cardiomyocytes and non-cardiomyocytes [(8-dOHG)(+)-index] were determined to quantify oxidative stress. RESULTS: Δ c-kit(+)CD45(-) cells (resident cardiac stem cells) were increased in newborns (2.2 ± 1.9/mm(2)) and decreased in children - 1.5 ± 0.7/mm(2), p < 0.01. The (8-dOHG)(+)-index was reduced by 43% in newborns and by 20% in children. CPB did not influence cardiac cell turnover; high cell proliferation was seen in newborns before and after CPB. Cardiopulmonary bypass significantly decreased the leucocyte infiltration in newborns to 40 ± 8%, p < 0.05, but not in children. Infiltration with eosinophils (eosinophils/CD45%) was completely abolished in the myocardium of newborns p < 0.05 and reduced to 22 ± 8% in children after CPB, n.s. CONCLUSIONS: Immediate response and remodeling of the myocardium to CPB differs between newborns, older infants and children. Especially an increased number of c-kit expressing CD45 cells after CPB were seen in neonates in comparison to children. The clinical value of such observation needs to be further assessed in larger cohorts of patients.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。